{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:55:42Z","timestamp":1792292142164,"version":"4.4.0"},"reference-count":82,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cutaneous melanoma is a malignant neoplasm with local and distant metastatic potential. When feasible, surgery is the first line of treatment in locoregionally advanced disease. Topical and intralesional treatments can be an alternative second-line treatment. The aim of this article was to perform a narrative review of the most widely used topical and intralesional treatments for locoregionally advanced melanoma. Diphenciprone, imiquimod and 5-florouracil were included as topical treatments and bacillus Calmette-Guerin, interleukin 2, rose bengal, talimogene laherparepvec and electrochemotherapy were included as intralesional treatments. Brief comments on other alternatives in development such as interferon-alpha, interleukin-12, ipilimumab and intralesional daromun are presented. Topical treatments generally have higher response rates in epidermal metastases than in deeper metastases. In addition, the larger the lesions, the worse they tend to respond to local treatments. Some reports show that combining certain systemic treatments and topical or intralesional therapies can improve response rates. It has also been described in a few papers that non-injected lesions may respond after the application of a local therapy in distant skin-metastases. Many of these intralesional treatments are being combined in different investigations with systemic immunotherapies, with the aim of obtaining synergic responses in those patients with refractory disease.<\/jats:p>","DOI":"10.3390\/cancers17010067","type":"journal-article","created":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T13:37:51Z","timestamp":1735738671000},"page":"67","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Topical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4262-0470","authenticated-orcid":false,"given":"Mar\u00eda","family":"Criado-Otero","sequence":"first","affiliation":[{"name":"Dermatology Department, Complejo Asistencial Universitario de Le\u00f3n, 24008 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Navedo-de las Heras","sequence":"additional","affiliation":[{"name":"Dermatology Department, Complejo Asistencial Universitario de Le\u00f3n, 24008 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5769-0502","authenticated-orcid":false,"given":"Elia","family":"Samaniego-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Dermatology Department, Complejo Asistencial Universitario de Le\u00f3n, 24008 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1615\/CritRevOncog.2016017124","article-title":"Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology","volume":"21","author":"Faries","year":"2016","journal-title":"Crit. Rev. Oncog."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"MMT23","DOI":"10.2217\/mmt-2019-0008","article-title":"Topical and Intralesional Therapies for In-Transitmelanoma","volume":"6","author":"Henderson","year":"2019","journal-title":"Melanoma Manag."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.det.2022.07.007","article-title":"Targeted Therapy and Immunotherapy in Melanoma","volume":"41","author":"Lazaroff","year":"2023","journal-title":"Dermatol. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Shalata, W., Attal, Z.G., Solomon, A., Shalata, S., Abu Saleh, O., Tourkey, L., Abu Salamah, F., Alatawneh, I., and Yakobson, A. (2024). Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115794"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Di Raimondo, C., Lozzi, F., Di Domenico, P.P., Campione, E., and Bianchi, L. (2023). The Diagnosis and Management of Cutaneous Metastases from Melanoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914535"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The Eighth Edition American Joint Committee on Cancer (AJCC) Melanoma Staging System: Implications for Melanoma Treatment and Care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-Transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of Care for the Management of Primary Cutaneous Melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"DePalo, D.K., and Zager, J.S. (2023). Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. Cancers, 15.","DOI":"10.3390\/cancers15051404"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jaad.2006.12.018","article-title":"Treatment of Extensive Cutaneous Metastatic Melanoma with Topical Diphencyprone","volume":"56","author":"Damian","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jso.23506","article-title":"Topical Immunotherapy with Diphencyprone for in Transit and Cutaneously Metastatic Melanoma","volume":"109","author":"Damian","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/DSS.0000000000001603","article-title":"Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience","volume":"44","author":"Veverka","year":"2018","journal-title":"Dermatol. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1590\/abd1806-4841.20187162","article-title":"Diphencyprone as a Therapeutic Option in Cutaneous Metastasis of Melanoma. A Single-Institution Experience","volume":"93","author":"Gibbons","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1744666X.2017.1286984","article-title":"Topical Immunotherapy with Diphencyprone (DPCP) for in-Transit and Unresectable Cutaneous Melanoma Lesions: An Inaugural Canadian Series","volume":"13","author":"Yeung","year":"2017","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.14314","article-title":"Topical Diphencyprone for the Treatment of Locoregional Intralymphatic Melanoma Metastases of the Skin; the 5-Year Norwich Experience","volume":"174","author":"Moncrieff","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bjps.2020.03.007","article-title":"Sequencing in Management of In-Transit Melanoma Metastasis: Diphencyprone versus Isolate Limb Infusion","volume":"73","author":"Lo","year":"2020","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.jaad.2020.04.023","article-title":"Response rates of cutaneous melanoma metastases to diphencyprone: A meta-analysis","volume":"83","author":"Calsavara","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s13555-023-00993-1","article-title":"Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature","volume":"13","author":"Vaienti","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2340\/00015555-3241","article-title":"Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment","volume":"99","author":"Tio","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0560.2009.01290.x","article-title":"Effectiveness of Imiquimod Limited to Dermal Melanoma Metastases, with Simultaneous Resistance of Subcutaneous Metastasis","volume":"37","author":"Turza","year":"2010","journal-title":"J. Cutan. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2006.07664.x","article-title":"Phase I\/II Study of Topical Imiquimod and Intralesional Interleukin-2 in the Treatment of Accessible Metastases in Malignant Melanoma","volume":"156","author":"Green","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/CMR.0b013e328345e95e","article-title":"Complete Regression of Subcutaneous and Cutaneous Metastatic Melanoma with High-Dose Intralesional Interleukin 2 in Combination with Topical Imiquimod and Retinoid Cream","volume":"21","author":"Ono","year":"2011","journal-title":"Melanoma Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaad.2015.06.060","article-title":"100% Complete Response Rate in Patients with Cutaneous Metastatic Melanoma Treated with Intralesional Interleukin (IL)-2, Imiquimod, and Topical Retinoid Combination Therapy: Results of a Case Series","volume":"73","author":"Shi","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1419113","DOI":"10.1080\/2162402X.2017.1419113","article-title":"Anti-Melanoma Immunity and Local Regression of Cutaneous Metastases in Melanoma Patients Treated with Monobenzone and Imiquimod; a Phase 2 a Trial","volume":"7","author":"Teulings","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.jaad.2011.10.028","article-title":"Combination Therapy of Imiquimod and Gentian Violet for Cutaneous Melanoma Metastases","volume":"67","author":"Arbiser","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10637-011-9717-2","article-title":"Topical Treatment of Cutaneous Metastases of Malignant Melanoma Using Combined Imiquimod and 5-Fluorouracil","volume":"30","author":"Florin","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CMR.0000000000000247","article-title":"Treatment of In-Transit and Metastatic Melanoma in Two Patients Treated with Ipilimumab and Topical Imiquimod","volume":"26","author":"Joseph","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/sj.jid.5700777","article-title":"Imiquimod Enhances the Systemic Immunity Attained by Local Cryosurgery Destruction of Melanoma Lesions","volume":"127","author":"Redondo","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/1346-8138.13197","article-title":"Local Cryosurgery and Imiquimod: A Successful Combination for the Treatment of Locoregional Cutaneous Metastasis of Melanoma: A Case Series","volume":"43","author":"Baradad","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.annder.2013.10.058","article-title":"In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery","volume":"141","author":"Elfatoiki","year":"2014","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/CJI.0000000000000098","article-title":"Treatment of In-Transit Melanoma with Intralesional Bacillus Calmette-Gu\u00e9rin (BCG) and Topical Imiquimod 5% Cream: A Report of 3 Cases","volume":"38","author":"Kibbi","year":"2015","journal-title":"J. Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/CJI.0b013e31827457bd","article-title":"Combined Intralesional Bacille Calmette-Gu\u00e9rin (BCG) and Topical Imiquimod for in-Transit Melanoma","volume":"35","author":"Kidner","year":"2012","journal-title":"J. Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/CJI.0000000000000319","article-title":"Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC\/Imiquimod Immunotherapy","volume":"43","author":"Sunshine","year":"2020","journal-title":"J. Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdcr.2022.09.006","article-title":"Topical Imiquimod in Combination with Brachytherapy for Unresectable Cutaneous Melanoma Scalp Metastases","volume":"31","author":"Yeh","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized Trial of Four Treatment Approaches for Actinic Keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG Immunotherapy of Malignant Melanoma: Summary of a Seven-Year Experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/1097-0142(197803)41:3<820::AID-CNCR2820410306>3.0.CO;2-N","article-title":"Severe Thrombocytopenia Following Intralesional BCG Therapy","volume":"41","author":"Norton","year":"1978","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF01789050","article-title":"Hypotension and Disseminated Intravascular Coagulation Following Intralesional Bacillus Calmette-Gu\u00e9rin Therapy for Locally Metastatic Melanoma","volume":"32","author":"Cohen","year":"1991","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jso.2930090609","article-title":"Risks of BCG Intralesional Therapy: An Experience with Melanoma","volume":"9","author":"Robinson","year":"1977","journal-title":"J. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Da Gama Duarte, J., Parakh, S., Andrews, M.C., Woods, K., Pasam, A., Tutuka, C., Ostrouska, S., Blackburn, J.M., Behren, A., and Cebon, J. (2018). Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Gu\u00e9rin Followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00411"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/1097-0142(197806)41:6<2456::AID-CNCR2820410654>3.0.CO;2-B","article-title":"Intralesional Treatment of Recurrent Metastatic Cutaneous Malignant Melanoma: A Randomized Prospective Study of Intralesional Bacillus Calmette-Guerin versus Intralesional Dinitrochlorobenzene","volume":"41","author":"Cohen","year":"1978","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10585-021-10100-3","article-title":"In-Transit Metastatic Cutaneous Melanoma: Current Management and Future Directions","volume":"39","author":"Patel","year":"2022","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2133.1994.tb03397.x","article-title":"Peritumoral Injections of Interleukin 2 Induce Tumour Regression in Metastatic Malignant Melanoma","volume":"130","author":"Gutwald","year":"1994","journal-title":"Br. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II Trial of Intralesional Therapy with Interleukin-2 in Soft-Tissue Melanoma Metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0001-7310(09)71905-2","article-title":"Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2","volume":"100","author":"Dehesa","year":"2009","journal-title":"Actas Dermosifiliogr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.25156","article-title":"High Response Rate after Intratumoral Treatment with Interleukin-2: Results from a Phase 2 Study in 51 Patients with Metastasized Melanoma","volume":"116","author":"Weide","year":"2010","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/1203475420988862","article-title":"Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma","volume":"25","author":"Khoury","year":"2021","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00262-019-02377-x","article-title":"Successful Combination Therapy of Systemic Checkpoint Inhibitors and Intralesional Interleukin-2 in Patients with Metastatic Melanoma with Primary Therapeutic Resistance to Checkpoint Inhibitors Alone","volume":"68","author":"Lehr","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00262-016-1944-0","article-title":"Combined Treatment with Ipilimumab and Intratumoral Interleukin-2 in Pretreated Patients with Stage IV Melanoma-Safety and Efficacy in a Phase II Study","volume":"66","author":"Weide","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Vidovic, D., Helyer, L.K., Pasternak, S., and Giacomantonio, C.A. (2023). Abscopal Responses in Patients with Metastatic Melanoma Involving Skin and Subcutaneous Tissues Treated with Intralesional IL2 plus BCG. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1160269"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","article-title":"Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma","volume":"22","author":"Thompson","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jso.24921","article-title":"Intralesional PV-10 for the Treatment of In-transit Melanoma Metastases\u2014Results of a Prospective, Non-randomized, Single Center Study","volume":"117","author":"Read","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jso.24311","article-title":"Intralesional PV-10 for in-Transit Melanoma-A Single-Center Experience","volume":"114","author":"Lippey","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/jso.24580","article-title":"Results of a Phase II, Open-Label, Non-Comparative Study of Intralesional PV-10 Followed by Radiotherapy for the Treatment of in-Transit or Metastatic Melanoma","volume":"115","author":"Foote","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_56","unstructured":"Provectus Biopharmaceuticals, Inc (2024, November 04). A Phase 1b\/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma; Clinical Trial Registration NCT02557321; clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02557321."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"17588359221083052","DOI":"10.1177\/17588359221083052","article-title":"Neoadjuvant Therapy for Melanoma: Rationale for Neoadjuvant Therapy and Pivotal Clinical Trials","volume":"14","author":"Witt","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination with Ipilimumab Versus Ipilimumab Alone in Patients with Advanced, Unresectable Melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e001621","DOI":"10.1136\/jitc-2020-001621","article-title":"Talimogene Laherparepvec Upregulates Immune-Cell Populations in Non-Injected Lesions: Findings from a Phase II, Multicenter, Open-Label Study in Patients with Stage IIIB-IVM1c Melanoma","volume":"9","author":"Malvehy","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/CJI.0000000000000265","article-title":"Response to the Rechallenge with Talimogene Laherparepvec (T-VEC) After Ipilimumab\/Nivolumab Treatment in Patient with Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC with Pembrolizumab","volume":"42","author":"Afzal","year":"2019","journal-title":"J. Immunother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant Talimogene Laherparepvec plus Surgery versus Surgery Alone for Resectable Stage IIIB-IVM1a Melanoma: A Randomized, Open-Label, Phase 2 Trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archderm.1996.03890350095015","article-title":"Bleomycin-Mediated Electrochemotherapy of Metastatic Melanoma","volume":"132","author":"Glass","year":"1996","journal-title":"Arch. Dermatol."},{"key":"ref_67","first-page":"863","article-title":"Electrochemotherapy with Cisplatin: Clinical Experience in Malignant Melanoma Patients","volume":"6","author":"Sersa","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2310\/7750.2006.00037","article-title":"Randomized Controlled Study of Electrochemotherapy in the Local Treatment of Skin Metastases of Melanoma","volume":"10","author":"Gaudy","year":"2006","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/bjd.15340","article-title":"Electrochemotherapy in the Treatment of Metastatic Malignant Melanoma: A Prospective Cohort Study by InspECT","volume":"176","author":"Kunte","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Milicevic, S., Cemazar, M., Ivancic, A.K., Gasljevic, G., Bosnjak, M., Sersa, G., and Peric, B. (2023). Electrochemotherapy of Melanoma Cutaneous Metastases in Organ Transplant Recipients: A Systematic Review of Preclinical and Clinical Studies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098335"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Quaresmini, D., Di Lauro, A., Fucci, L., Strippoli, S., De Risi, I., Sciacovelli, A.M., Albano, A., Achille, G., Montepara, M., and Russo, S. (2021). Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.742666"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.seminoncol.2015.02.012","article-title":"Immune Checkpoint Blockade and Interferon-\u03b1 in Melanoma","volume":"42","author":"Rafique","year":"2015","journal-title":"Semin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/1097-0142(19880315)61:6<1071::AID-CNCR2820610603>3.0.CO;2-T","article-title":"Intralesional interferon-alpha therapy in advanced malignant melanoma","volume":"61","author":"Block","year":"1988","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12967-015-0473-5","article-title":"Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: Results from a phase I trial in advanced melanoma","volume":"13","author":"Rozera","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Gao, W., Pan, J., and Pan, J. (2022). Antitumor Activities of Interleukin-12 in Melanoma. Cancers, 14.","DOI":"10.3390\/cancers14225592"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/2326-6066.CIR-19-0359","article-title":"Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses","volume":"8","author":"Greaney","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","article-title":"Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma","volume":"26","author":"Algazi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"64390","DOI":"10.18632\/oncotarget.10453","article-title":"A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma","volume":"7","author":"Ray","year":"2016","journal-title":"Oncotarget"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-015-1704-6","article-title":"Intralesional administration of L19-IL2\/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study","volume":"64","author":"Danielli","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.2217\/fon-2019-0433","article-title":"Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB\/C melanoma","volume":"15","author":"Miura","year":"2019","journal-title":"Future Oncol."},{"key":"ref_81","unstructured":"The Netherlands Cancer Institute (2024, November 06). Neo-Adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB\/C\/D-IV M1a) Melanoma with Injectable Disease; Clinical Trial Registration NCT04330430; clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04330430."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Boulva, K., Apte, S., Yu, A., Tran, A., Shorr, R., Song, X., Ong, M., and Nessim, C. (2021). Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13081905"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/67\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:45Z","timestamp":1760115345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/67"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17010067"],"URL":"https:\/\/doi.org\/10.3390\/cancers17010067","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}